News
-
-
PRESS RELEASE
In Support of Possible Expedited Approval Pathway for Crofelemer for Treatment of Microvillus Inclusion Disease (MVID), Jaguar Health Submits Amended Protocol to FDA for Ongoing Placebo-Controlled Clinical Trial
Jaguar Health submits amended protocol to FDA for crofelemer in pediatric MVID patients to potentially extend lives and reduce parenteral support by up to 37% -
-
PRESS RELEASE
Jaguar Health Reports Third Quarter 2025 Financials: Net Q3 2025 Revenue Up Approximately 4% Versus Net Q2 2025 Revenue
Jaguar Health, Inc. reports proof-of-concept trial shows crofelemer potential for MVID patients, financial results revealed, FDA meeting outcome, and upcoming investor webcast -
-
PRESS RELEASE
Jaguar Health to Hold Investor Webcast Monday, November 17 at 8:30 AM Eastern Regarding Q3 2025 Financials & Corporate Updates
Jaguar Health, Inc. (NASDAQ:JAGX) to file Earnings Report on Form 10-Q for quarter ended September 30, 2025. Investor webcast on November 17, 2025 at 8:30 a.m. Eastern to review financials and provide corporate updates -
-
PRESS RELEASE
Jaguar Health Provides Recap of November 8, 2025 Presentation on Groundbreaking Results of Proof-of-Concept Study of Crofelemer for Treatment of Pediatric Intestinal Failure at NASPGHAN Annual Meeting
Crofelemer shows promising results in reducing total parenteral support for MVID patients, presented at NASPGHAN. Jaguar Health's investigation explores breakthrough benefits for pediatric patients with intestinal failure -
-
PRESS RELEASE
REMINDER: Initial Groundbreaking Results of Proof-of-Concept Study of Jaguar Health's Crofelemer for Treatment of Pediatric Intestinal Failure to be Presented November 8, 2025 at North American Society for Pediatric Gastroenterology, Hepatology and Nutrit
Ongoing trial of crofelemer in UAE shows reduction in parenteral support for pediatric intestinal failure patients. Breakthrough in MVID and SBS-IF treatment
